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The steroid receptor RNA activator (SRA) is a unique modulator of steroid receptor transcriptional activity,
as it is able to mediate its coregulatory effects as a RNA molecule. Recent findings, however, have painted a
more complex picture of the SRA gene (SRA1) products. Indeed, even though SRA was initially thought to
be noncoding, several RNA isoforms have now been found to encode an endogenous protein (SRAP), which
is well conserved among Chordata. Although the function of SRAP remains largely unknown, it has been
proposed that, much like its corresponding RNA, the protein itself might regulate estrogen and androgen
receptor signaling pathways. As such, data suggest that both SRA and SRAP might participate in the
mechanisms underlying breast, as well as prostate tumorigenesis.This review summarizes the published
literature dealing with these two faces of the SRA gene products and underscores the relevance of this
bifaceted system to breast cancer development.
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Estrogen and breast cancer
Through its mitogenic action on breast epithelial cells,
estrogen not only controls the biology and the
development of the normal mammary gland, but also
participates in breast tumor growth promotion and breast
cancer progression (for a review see [Jensen and Jordan,
2003]). Estrogen action is mainly mediated through two
estrogen receptors (ERs), α and β [Green et al., 1986;
Mosselman et al., 1996; Ogawa et al., 1998], that belong
to the steroid/thyroid/retinoic acid receptors superfamily
and primarily act as ligand-dependent transcription factors
[Evans, 1988].These receptors share the same functional
and structural organization: a variable N-terminal region
containing a hormone-independent activation domain
AF-1; a DNA binding domain (DBD) responsible for the
specificity of DNA recognition; and a C-terminal extremity
containing both the ligand binding domain (LBD) and a
ligand-dependent activation domain AF-2. Once bound
to their ligand, the receptors undergo conformational
changes, dimerize and specifically recognize regulatory
DNA sequences (hormone responsive elements, HRE)
upstream of target genes. Activated receptors, through
a dynamic interplay involving coregulators, chromatin
remodeling, histone modification and proteosomal activity,
direct the assembly and the stabilization of a pre-initiation
complex that will ultimately lead to the transcription of
these genes [Dennis and O'Malley, 2005; McKenna et
al., 1999; Shibata et al., 1997; Xu, 2005] .
Acknowledgement of the importance of estrogen signaling
pathways in the growth of a large number of breast
cancers has led to the development of endocrine
therapies. For example, Tamoxifen, through competitive
binding to ERs, antagonizes the mitogenic action of
estrogen. It has been successfully used as an endocrine
therapy for more than 20 years and an estimated 400,000
women are alive today because of long-term adjuvant
Tamoxifen therapy [Jordan and Morrow, 1999].The
demonstration that Tamoxifen could also prevent the
occurrence of breast cancer in women at risk [Fisher et
al., 1998; Fisher et al., 2000] raised the hope that many
more lives will be spared through the better understanding
and manipulation of ER signaling pathways.
Over the last few years, it has become apparent that the
balance between coactivators and corepressors, which
respectively enhance and repress receptor activity, has
an important role in the control of steroid receptor action
in a given tissue [Lonard and O'Malley, 2006]. A direct
participation of this balance during breast tumorigenesis
and cancer progression is now suspected, and a search
for possible means to control it and develop new targets
for preventive and therapeutic endocrine strategies has
started worldwide [Hall and McDonnell, 2005; Perissi and
Rosenfeld, 2005].
In this context, the discovery of the steroid receptor RNA
activator, which not only differentially coactivates ER-α
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involved in the regulation of steroid receptor activity,
brings a new layer of complexity.
Figure 1.  SRA1 genomic structure and transcripts. A. Original
SRA transcripts.Three SRA sequences (I, II and II) were originally
described, differing in their 5' and 3' extremities, but sharing a central
core sequence depicted in light blue [Lanz et al., 1999]. One sequence
has been registered with the NCBI nucleotide database (AF092038).
Alignment with chromosome 5q31.3 genomic sequence is provided.
Introns and exons are represented by black lines and blue boxes,
respectively. B. Currently identified SRA transcripts.Thirteen sequences,
corresponding to all SRA transcripts identified to date, have been aligned
with the genomic sequence of chromosome 5q31.3 (AC005214).White
and black strips indicate the position of SRAP translation start and stop
codons, respectively.White and black stars correspond to a point mutation
in exon-2 (position 98 of the core: U to C) and a point mutation followed
by a full codon (position 271 of the core: G to CGAC), respectively.
An atypical coregulator: the noncoding
steroid receptor RNA activator (SRA)
Discovery
In an effort to discover new coregulators interacting with
the AF-1 domain of the progesterone receptor (PR), Lanz
et al. screened a human B-lymphocyte library using this
domain as bait in a typical Yeast two-hybrid assay [Lanz
et al., 1999].They identified a new clone they called SRA,
for steroid receptor RNA activator. Pursuing the analysis
of the transcript corresponding to this clone, they
subsequently identified three human SRA cDNAs (Figure
1A; SRA I, II and II) via conventional screening of skeletal
muscle, heart and HeLa S3 cell line cDNA libraries.These
sequences differed in their 5' and 3' extremities, but
shared a central 687 bp core region (Figure 1A).
Only one of these sequences (AF092038) has been
registered in the nucleotide database at the National
Center for Biotechnology Information (NCBI).This
sequence fully aligns with a portion of chromosome
5q31.3, defining the SRA1 gene overlapping 5 exonic
and 4 intronic regions.The core sequence, identified as
common among the 3 original cDNAs, encompasses
exon-2 to exon-5 (Figure 1A).The SRA1 gene is flanked
on the 5' terminus by the Fe64-LIKE2 gene (Fe64L2) and
on the 3' reverse strand by the gene encoding the
eukaryotic translation initiation factor 4E binding protein
3 (EIF4EBP3). Despite their close proximity, expression
pattern analyses confirmed that SRA was an autonomous
gene whose expression was independent of the
concurrent expression of the flanking genes [Lanz et al.,
2002].
In their original report, Lanz et al. presented solid
functional evidence supporting the role of SRA as a
steroid receptor coactivating molecule. Using
cotransfection and reporter assays, they showed that
SRA selectively enhanced the AF-1 activity of class I
nuclear receptors (i.e., steroid receptors: androgen
receptor "AR", ER-α, progesterone receptor "PR", and
glucocorticoid receptor "GR"), while it did not affect, in
their model, the activity of class II nuclear receptors
(thyroid hormone "TR-β", all-trans retinoic acid receptor
"RAR-γ", 9-cis retinoic acid "RXR-γ", and peroxisome
proliferator-activated receptor "PPAR-γ).
SRA is a RNA coactivator
Surprisingly, although the Yeast two-hybrid screening
system is based upon protein-protein interaction, Lanz
et al. reported that their original Gal/SRA fusion clone
contained a stop codon upstream of the SRA sequence.
This construction, even though unable to generate a
Gal/SRA fusion protein, was however required for the
growth of the yeast colony.This led the authors to
speculate that SRA, as a RNA, might have acted as a
bridge between the PR-AF-1/Gal4 DNA binding domain
and endogenous yeast transcriptional activators. All
attempts by these authors to generate SRA protein
products in vitro using the three original SRA cDNAs were
unsuccessful, except when carboxyl-, but not N-terminal,
fusions of SRA with GST or GAL4 were made [Lanz et
al., 1999].This suggested that none of the ATG codons
contained in the three identified SRA transcript sequences
could be used for the initiation of an efficient translation.
Because the concept of an RNA coactivating steroid
receptor was entirely unprecedented, Lanz et al.
performed a series of convincing experiments to prove
an action at the RNA, rather than the protein level.They
first established that SRA was able to coactivate the
progesterone receptor in an open reading
frame-independent manner by showing that all three
alternate open reading frames fused to the translation
initiation region of the HSV-thymidine kinase were able
to activate transcription with similar efficiency.
Furthermore, the introduction of point mutations changing
any putative open reading frame or adding premature
translation stop codons did not affect the ability of SRA
to coactivate PR-mediated transcription. Finally, inhibition
of de novo protein synthesis with cycloheximide had no
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Review Bifaceted SRA/SRAP system and breast cancerFigure 2.  Alignment of human, mouse and rat core SRA RNA sequences. Nucleotide sequences corresponding to structures shown to be
functionally relevant (STR1, 9, 5, 10, 7, 11 and 12) are boxed in blue [Lanz et al., 2002]. STR5 structure, containing an important pseudouridylation
site at position 207 ([Zhao et al., 2007], and see the subsection "Effect of SRA on ER-α and ER-β-mediated transcription") is shaded in dark blue. AUG
codon at position 208 in the rat sequence (and referred to in the subsection "SRAP function") is boxed in red.
effect on the coactivating properties of SRA on
glucocorticoid receptor-mediated transcription, but
efficiently reduced the activity of other known coactivator
peptides, such as the steroid receptor coactivator 1
(SRC-1) and the CREB-binding protein (CBP). Altogether,
these data confirmed that the observed coactivator role
of SRA was mediated through a RNA transcript rather
than any peptide product.
SRA functional core
SRA core sequence, found to be necessary and sufficient
for SRA to act as a coactivator [Lanz et al., 1999], is fairly
well conserved between rodent and human (Figure 2).
Serial removal of both ends of the core region reduced
SRA coactivation. Removed sections however, were not,
by themselves, sufficient for coactivation [Lanz et al.,
1999; Lanz et al., 2002].These results hinted that SRA
functional regions were not limited to a single, discrete
domain, but rather to several sections distributed
throughout the whole core sequence. Low-resolution RNA
modeling [Zuker, 2003] predicts several substructures in
SRA secondary structure (Figure 3).Through mutation
experiments, six secondary structural motifs (STR-1, -9,
-10, -7, -11 and -12) individually participating in SRA’s
coactivator role have been identified [Lanz et al., 2002].
These observations not only underlined the functional
importance of SRA structural features, but also suggested
their potential role(s) in modulating the ability of SRA to
interact with other molecules.
Figure 3.  Schematic profile of the predicted secondary structure
of human core SRA RNA. The secondary structure profile of SRA core
sequence has been modeled using Mfold software [Zuker, 2003]. Detailed
structure of STR1, 9, 5, 10, 7, 11 and 12 [Lanz et al., 2002] is provided.
The position of Uridine residue 207 in STR-5, found to be a site of
pseudouridylation (see the "Emerging mechanism of action subsection"),
is shown by a blue Ψ.
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SRA, in many different cell models, increases E2-induced
activity of both full-length ER subtypes [Cavarretta et al.,
2002; Coleman et al., 2004; Deblois and Giguere, 2003;
Hatchell et al., 2006; Klinge et al., 2004; Lanz et al., 1999;
Shi et al., 2001;Watanabe et al., 2001; Zhao et al., 2007].
Functional analyses performed with constructions lacking
the AF-1 domains showed that SRA coactivates the AF-2
regions of ER-α and ER-β [Coleman et al., 2004; Deblois
and Giguere, 2003].This somewhat contradicts the earlier
results, which showed that AF-1-deleted PR and GR
mutants were not activated by SRA, and that the
N-terminal domain was needed for this RNA to coactivate
steroid receptors [Lanz et al., 1999].This suggests that
either estrogen receptors have differential SRA-mediated
mechanisms and/or that the cell system used or HREs
investigated have a critical effect on the observed action
of SRA on a given receptor.The impact of the sequence
of EREs used to drive the expression of reporter genes
on measured SRA effects has indeed been reported
[Klinge et al., 2004].
SRA can also enhance AF-1 activity of ER-α, but not that
of ER-β [Coleman et al., 2004; Deblois and Giguere,
2003]. Conflicting reports have been published regarding
the role played by E2 and the phosphorylation of the S118
residue in ER-α in this SRA effect [Coleman et al., 2004;
Deblois and Giguere, 2003]. In the study by Deblois et
al., a construction consisting of ER-α AF-1/DNA binding
domain (hence not containing the ligand binding domain)
was active only when SRA was present and E2 added.
The phosphorylation of S118 residue, known to be critical
for ER-α activity [Ali et al., 1993; Kato et al., 1995; Kato
et al., 2000; Le Goff et al., 1994;Weigel and Moore,
2007a;Weigel and Moore, 2007b], was necessary to see
this effect [Deblois and Giguere, 2003]. It was therefore
proposed that E2, even though unable to bind the receptor
itself, was activating the mitogen-activated protein kinase
(MAPK) pathway and indirectly induced the S118
phosphorylation necessary for SRA to act as a coactivator
of the AF-1 region. In the study by Coleman et al., a fusion
protein consisting of ER-α AF-1 domain fused to the DBD
domain of Gal 4 induced transcription in the presence of
SRA [Coleman et al., 2004]. In this system, neither E2
treatment or phosphorylation of S118 was needed for
SRA to coactivate ER-α AF-1 activity.These opposite
findings may again result from the different systems used,
but they also raised the possibility of a role played by
ER-α sequences (mainly DBD) present in the first report,
but absent in the second study.The DBD of nuclear
receptors is indeed known to be the target of coregulatory
molecules [Ko et al., 2002; Mathur et al., 2001;Tao et
al., 2001]. Further studies are warranted to further
address this issue.
The ability of SRA to enhance, in the presence of E2,
AF-2 activity of both estrogen receptors, but only ER-α
AF-1, suggests at least two different mechanisms of
action of this SRA in participating in ligand-mediated
transcription.The observation that it can also coactivate
the response of ER-α, but not ER-β, to Tamoxifen
[Coleman et al., 2004], raises the possibility that, in
addition, it could participate in the events leading to the
known differential response of these two receptors to
antagonist molecules [Barkhem et al., 1998;Watanabe
et al., 1997].
Emerging mechanism of action
Several studies have now been published shedding light
on SRA’s mechanism of action (Table 1). SRA action
appears not to be solely limited to enhancing steroid
receptor activity. Indeed, it was found to increase the
activity of other nuclear receptors, as well.The
discrepancy with the original findings in the ability to
modulate the activity of nuclear receptors other than
steroid receptors may, as shown for ERs, result from
differences in cell-type and reporter systems used. It is
also likely that SRA’s coactivator role on a given nuclear
receptor will depend upon the presence or absence of
other regulatory molecules (see below).The recent report
that SRA modulates the activity of MyoD, a transcription
factor participating in skeletal myogenesis [Caretti et al.,
2006], suggests that the role of SRA might be broader
than originally predicted.
Several proteins participating in the formation of
ribonucleoprotein complexes with SRA RNA have now
been identified (Table 2).These include the transcription
factors whose activity is increased by SRA, as well as
accessory proteins acting as positive or negative
regulators of nuclear receptor activity.
Association with nuclear receptors
Using an in vitro system consisting of extracts from
Xenopus oocytes, it was found that SRA could form
complexes with full-length AR, but not with AF-1-deleted
AR (ΔAF-1-AR) mutants [Lanz et al., 1999].This suggests
that sequences within this domain directly or indirectly
participate in the association of SRA/NR. Interestingly, it
has been shown that SRA RNA could directly bind to a
40 amino acid long segment immediately following the
second Zinc finger of the DNA binding domain of TR-α1,
TR-α2 and TR-β [Xu and Koenig, 2004; Xu and Koenig,
2005], emphasizing that this nuclear receptor might have
different options/sites to recruit SRA.
Nuclear receptor coactivators
(i) SRC-1 and TIF2 - SRC-1 and TIF2 belong to the p160
family of nuclear receptor coactivators [Xu and Li, 2003].
These proteins, which directly bind to the AF-2 region of
nuclear receptors upon agonist binding, are also able to
interact with the AF-1 domain of ERs [Dutertre and Smith,
2003; Metivier et al., 2001; [Tremblay et al., 1999].They
therefore participate in the functional synergy existing
between AF-1 and AF-2, as well as in the recruitment of
other coregulators [McKenna et al., 1999; Smith and
O'Malley, 2004; Xu, 2005]. SRA and SRC-1 can be
associated in a large ribonucleoprotein complex of
600-700 kDa, which does not contain the other
coactivators p300 or CBP [Lanz et al., 1999].This led to
the hypothesis that SRA might act by modulating the
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activity of very distinct coactivator complexes.
Interestingly, SRA can form complexes with ΔAF-1-AR
in the presence of SRC-1 [Lanz et al., 1999], confirming
the ability of activated receptors to recruit SRA through
different mechanisms.
(ii) p68 and p72 - p68 and p72 belong to the large DExD/H
box family of RNA-helicases, which are involved in all
aspects of RNA biology, from synthesis and splicing to
transport and translation [Fuller-Pace, 2006]. p68/72
directly interact with all members of the SRC-1 family,
with the AF-1 region of ER-α, but not other nuclear
receptors (including ER-β) and with SRA [Watanabe et
al., 2001]. As such, they are able to specifically coactivate
not only the agonist-induced AF-2 activity, but the
ligand-independent or antagonist-induced AF-1 activity
of this receptor as well. It should be stressed that p68
interaction with ER-α is potentiated by the phosphorylation
of ER-α [Watanabe et al., 2001]. Interestingly, the physical
interaction of p68/72 with SRA is required for these
helicases to act as ER-α-specific coactivators.This
suggests a crucial role played by SRA in the proper
folding/interplay of the different molecules needed to lead
to an efficient transcription of target genes. More details
on the possible roles of SRA/p68/p72 interactions can be
found in a recently published review [Caretti et al., 2007].
(iii) Pus1p and Pus3p - Pus1p and Pus3p belong to the
pseudouridine synthase (PUS) family of proteins, which
isomerize uridine (U) to pseudouridine (Ψ) in noncoding
RNAs such as tRNA, rRNA or snRNA [Charette and Gray,
2000; Ferre-D'Amare, 2003]. Such post-transcriptional
modification was found to alter the structural and rigidity
features of the target RNAs and to modulate RNA/RNA,
as well as RNA/protein interactions. Pus1p and Pus3p
pseudouridylate several common, as well as different
residues within SRA. Both Pus proteins physically interact
with the first Zinc finger of the DNA binding domain of the
class II nuclear receptor RAR [Zhao et al., 2007; Zhao et
al., 2004]. In the presence of either Pus protein,
pseudouridylated SRA becomes able to coactivate this
class of nuclear receptor. In contrast, only Pus1p
associates with class I receptors and synergizes with
SRA to act as a coactivator of these receptors. It was
shown that the mutagenesis of a site of pseudouridylation
common to both Pus1p and Pus3p, and located in the
STR-5 substructure (change from U to A, position 207,
see Figure 2 and Figure 3), leads to an overall
hyper-pseudouridylation of SRA. Interestingly, in such a
hyper-pseudouridylated state, SRA switches from being
a coactivator of class I receptors to a dominant negative
regulator. Pseudouridylation of SRA by Pus1p and Pus3p
therefore appears as a major player in regulating the
effect of this RNA on nuclear receptor activity.
Proteins antagonizing nuclear receptor activity
(i) SHARP (SMRT/HDAC1 Associated Repressor Protein)
- SHARP was originally identified [Shi et al., 2001] as a
protein directly interacting with the C-terminal extremity
of the nuclear receptor corepressor SMRT (silencing
mediator of retinoic acid and thyroid hormone receptor).
SHARP contains a transcriptional repressor domain (RD)
and an RNA-interacting domain (RRM).Through the
former domain, SHARP is able to recruit HDAC1 and
SMRT, whereas the latter domain is needed to interact
with STR-7, one of the important functional/structural
domains of SRA involved in SRA action [Hatchell et al.,
2006; Lanz et al., 2002; Shi et al., 2001]. Full-length
SHARP, but not RD only, repressed SRA coactivation of
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ER and GR. It has been suggested that this repressive
action might result from the sequestration of SRA and
associated coactivators or from the recruitment of
corepressor on the site of target genes.
(ii) SLIRP (SRA stem-loop interacting RNA binding
protein) - SLIRP was recently identified as a protein
binding to STR7 [Hatchell et al., 2006].This small (109
amino acids) protein mainly consists of a RNA recognition
motif (RRM) and represses nuclear receptor activity
through binding SRA. SLIRP, which is recruited on the
promoter of target genes, also controls the amount of
SRA associated with SRC-1. SLIRP siRNA experiments
showed a reduced level of nuclear receptor corepressor
(NCoR) associating with ER on the pS2 target gene
promoter in the absence of ligand.This led the authors
to hypothesize that SLIRP could participate in the
recruitment of this corepressor to the promoter of target
genes. Interestingly, the majority of the endogenous
SLIRP is found in the mitochondria, raising the possibility
that SRA may also have a role in this cell compartment.
An emerging model of the mechanism of action of SRA
on ER-α is presented in Figure 4. It should be stressed
that the presence of molecules such as p68, SLIRP or
Pus1/3p at the promoter of target genes has been
demonstrated by Chromatin Immunoprecipitation (ChIP)
assays [Caretti et al., 2006; Hatchell et al., 2006; Zhao
et al., 2007; Zhao et al., 2004], though the recruitment of
SRA RNA at these sites remains to be experimentally
established. Similarly, further studies are needed to
establish the exact kinetics of events involving these
different partners, as well as the potential differential
effects of receptor ligands.The active participation of
SRA RNA in the different interactions between the
receptor and its coregulators has however led to the
proposition that SRA serves as a “gasket” or “molecular
adapter”, facilitating the interactions between these
molecules. It should be emphasized that the exact
participation of the different SRA secondary substructures
(detailed in Figure 3) in these physical interactions
remains to be elucidated. Indeed, as of today, only STR-7
has been clearly shown, through its ability to be
recognized by SLIRP and SHARP, to modulate the
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Further analyses are therefore needed to establish the
involvement of other SRA substructures in establishing
adequate physical interfaces between SRA RNA and its
interacting proteins.The observation that
pseudouridylation, known to stabilize RNA structures,
affects SRA function [Zhao et al., 2007], strongly suggests
that this posttranscriptional modification might also
participate in the establishment of functional interfaces
between the different partners.
SRA expression and relevance to breast cancer
Different SRA transcripts, detected by Northern blot with
apparent migration size of 0.7, 0.85, and ~1.5 kb, have
been observed in human tissues [Lanz et al., 1999]. SRA
appears highly expressed in liver, skeletal muscle, adrenal
gland and the pituitary gland, whereas intermediate
expression levels are seen in the placenta, lung, kidney
and pancreas. Interestingly, brain and other typical
steroid-responsive tissues such as prostate, breast, uterus
and ovary contained low levels of SRA RNA [Lanz et al.,
2003; Lanz et al., 1999]. In all established cancer cell
lines, the 0.85 kb SRA appears to be the main detectable
transcript [Lanz et al., 1999]. It should be stressed that
the additional 0.7 kb SRA transcript is also observed in
cells from breast origin (MCF-7, T47-D). Altogether, SRA
is expressed in most tissues.The presence of different
transcripts, together with their relative levels of
expression, suggest alternative mechanisms of regulation
are likely to be tissue- and cell type-specific.
Using RT-PCR targeting core SRA sequences, several
reports have shown that SRA expression was increased
during breast, uterus and ovarian tumorigenesis
[Hussein-Fikret and Fuller, 2005; Lanz et al., 2003;
Leygue et al., 1999; Murphy et al., 2000]. Interestingly,
SRA overexpression might characterize particular
subtypes or subgroups of lesions. Indeed, serous ovarian
tumors expressed higher levels of SRA than granulosa
cell tumors or mucinous cystadenocarcinoma
[Hussein-Fikret and Fuller, 2005]. Similarly,
ER-α-positive/PR-negative breast tumors expressed more
SRA than ER-α-positive/PR-positive breast tumors
[Leygue et al., 1999], whereas Tamoxifen-sensitive and
-resistant breast tumors express similar levels [Murphy
et al., 2002].
A possible direct involvement of SRA in the mechanisms
underlying breast tumorigenesis and tumor progression
has been proposed [Lanz et al., 2003; Leygue et al.,
1999].The generation of transgenic mice has however
demonstrated that overexpression of the core SRA
sequence in the mammary gland was not sufficient per
se to induce tumorigenesis [Lanz et al., 2003]. Indeed,
even though elevated proliferation leading to the formation
of preneoplastic lesions were found to take place in the
mammary gland of transgenic mice, none of these lesions
led to the development of malignant tumors.The inability
of the core SRA to lead, by itself, to a full malignant
phenotype may result from the lack of other necessary
mechanisms involving additional factors. It may also, as
underlined by Lanz et al., result from the high level of
apoptosis observed in transgenic mice breast tissue [Lanz
et al., 2003]. Apoptosis, through cell loss, may indeed
slow down the growth of potential tumor cells.The
interpretation of the phenotype observed in these
transgenic mice is further complicated by the ability of
SRA to regulate the activity of both ERs and PRs. Indeed,
both receptors are known to play crucial roles in normal,
as well as abnormal mammary gland biology [Anderson
and Clarke, 2004; Conneely et al., 2003; Hennighausen
and Robinson, 1998; Curtis Hewitt et al., 2000].The
increased expression of PR (known target gene of ER)
in the mammary gland of transgenic virgins, together with
the apparent phenotype similarities with previously
generated PR-A transgenic mice [Shyamala et al., 1998]
led the authors to propose that they were observing a
SRA-enhanced ER transactivation of PR expression [Lanz
et al., 2003] . Altogether, the phenotype observed likely
results from a complex interplay involving steroid receptor
activities and possibly other still to be discovered
SRA-regulated factors.
Coding SRAs and SRA protein (SRAP)
Heterogeneity of SRA transcripts
Several additional human SRA sequences have now
been deposited in the nucleotide database of the National
Center for Biotechnology Information (Figure 1B). As
expected, most of these sequences contain an intact core
sequence (exon-2 to exon-5) and differ in their
5'-extremity.The presence of a full core sequence
suggests that these isoforms could be fully functional as
transcriptional coactivators. Compared to the original
AF092038 SRA sequence, some of the sequences
contain a point mutation in exon-2 (position 98 of the core:
U to C) or a point mutation followed by a full codon
(position 271 of the core: G to CGAC), which likely
correspond to gene polymorphisms [Emberley et al.,
2003].
Four sequences have a full or partial retention of intron-1.
Interestingly, the 5' end of six sequences consists of an
extended exon-1, which contains two methionine codons
in frame with a large open reading frame defining a
236/237 amino acid long peptide.These cDNAs, as
opposed to the original SRA, were translatable in vitro,
as well as in vivo, leading to the production of a protein
localized both in the cytoplasm and the nucleus [Emberley
et al., 2003]. Altogether, this raised the possibility that
these transcripts, even though still functional at the RNA
level through their core sequence, might also encode a
protein.
Sequence conservation of the protein encoded
by coding SRAs
The sequence of the protein encoded by SRA, referred
to as SRAP, is highly conserved in all Chordata (Figure
5).The most conserved amino acids define two distinct
domains (N- and C-terminal) that represent the typical
signature of this new family of proteins, and which are
likely both participating in SRAP function.The presence
of an endogenous SRA protein (SRAP) has now been
confirmed in the muscle of several vertebrates including
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Review Bifaceted SRA/SRAP system and breast cancerFigure 4.  Emerging putative model of SRA RNA action on ER-α signaling. A. Activation of ER-α gene expression by SRA RNA. Pus1p (green
wheel), which is able to bind the DNA binding domain of all nuclear receptors, pseudouridylates specific SRA RNA uridine residues, leading to an
optimum configuration of this RNA.The resulting SRA-ψ (cross), could now form a stabilizing complex with p68 (green crescent able to bind SRC-1
and ER-α AF-1 region) and SRC-1 (green horseshoe).Transcription of target genes with suitable ERE (red elements on DNA) will occur. It should be
stressed that the physical presence of SRA RNA at the level of promoter has not yet been established experimentally. Similarly, the kinetics of events
involving these molecules at the promoter site, as well as the possible effect of specific ligands (red sphere), remain to determined. B. Inhibition of SRA
RNA-mediated ER-α. SLIRP (hollow red cylinder) and SHARP (hollow trapeze) act as negative regulators. It has been proposed that they might act
by sequestrating SRA, by destabilizing the complex SRA/SRC-1 or by recruiting the nuclear receptor corepressor N-CoR at the promoter region of
silenced genes. ER-α ligand binding domain, DNA binding domain and AF-1 domain are shown in blue horseshoe, flat elliptic cylinder and blue cylinder,
respectively.
mouse, birds, cows and humans [Chooniedass-Kothari
et al., 2004].This protein is also ubiquitously found in
human cancer cell lines from the breast [Emberley et al.,
2003], the prostate [Kurisu et al., 2006], and other tissues
as well (Leygue et al., personal observations), even
though levels of expression appear to vary from one cell
type to another.
SRAP expression in breast tumors
In a small subset of patients with primary ER-α-positive
tumors that was subsequently treated with Tamoxifen, it
has been found that SRAP was detectable by Western
blot in some patients, but not others [Chooniedass-Kothari
et al., 2006]. Interestingly, the apparent overexpression
of SRAP in some cases correlated with an overall better
survival of the patients.This indicates that SRAP
expression is differentially regulated in breast tumors.
This also suggests that an increase in SRAP expression
might characterize a less aggressive type of tumor, and
possibly that this protein contributes to the overall
improved outcome after Tamoxifen treatment. Further
expression and functional studies are needed to clarify
this issue.
SRAP function
To date, most studies have focused mainly on the
coactivating function of the noncoding SRA. Exact
functions of SRAP therefore remain generally
underexplored. Nonetheless, SRAP was shown to directly
interact with the AF-2 domain of AR in vitro [Kawashima
et al., 2003]. In this study, it was proposed that SRAP,
instead of SRA RNA, was coactivating the response to
androgen.This proposition is based on the observation
that an introduced shift in SRAP reading frame inhibited
the translation of the SRAP protein studied, and led to
the loss of coactivation function.This appears to be in
direct contrast with the observations of Lanz et al. [Lanz
et al., 2003]. Besides the already underlined differences,
possibly resulting from the cell type and reporter system
used, alternative hypotheses can be raised to explain
these apparently contrasting results. Indeed, while
suppression of SRAP protein production leads to a
suppression of coactivating activity, which certainly
suggests a functional role of the protein studied, it does
not necessarily exclude the possibility that SRA RNA can
be a coactivator. Indeed, the sequence used by
Kawashima et al. in their experiments corresponds to the
coding sequence of a short putative rat SRAP starting at
the AUG codon at position 208 in Figure 2 [Kawashima
et al., 2003].This construct is therefore missing the 5'
end of the SRA core and might generate a nonfunctional
SRA RNA. It should also be stressed that the SRAP rat
protein analyzed in these experiments was also missing
the first domain of SRAP (as defined in Figure 5).This
region is strongly conserved in Chordata. It is therefore
reasonable to assume it might have an important
functional role.The transient transfection of full-length
SRA coding sequence also led to an activation of the
response to androgen [Kurisu et al., 2006].This contrasts
with the decreased response to estrogen observed in
breast cells stably transfected with coding SRA, which
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Review Bifaceted SRA/SRAP system and breast cancerFigure 5.  Alignment of SRA protein-related sequences. Putative SRA protein sequence homologues corresponding to 20 Chordata species are
aligned.The numbers indicated on top of the alignment correspond to amino acid numbering of the human SRAP isoform 1. Amino acids conserved
in all species are in red letters, whereas those observed in between 70% and 100% of all species are in yellow.Within the consensus sequence, #, !
and $ stand for D or E, I or V, M or L, respectively.
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these cells [Chooniedass-Kothari et al., 2006].
Table 3.  Proteins forming complexes with SRAP. Proteins identified
by protein sequencing as coimmunoprecipitating with SRAP in nuclear
(n) or cytoplasmic (c) extracts of HeLa cells [Jung et al., 2005a] are listed.
Examples of proteins considered, using the Gene Ontology terms
(biological processes: GOTERM-BP or molecular functions: GOTERM-MF,
http://www.geneontology.org/), as molecular chaperones, involved in DNA
replication, RNA processing, regulation of transcription or transport are
highlighted in orange, green, blue, yellow and pink, respectively.
Interestingly, SRAP has recently been shown to interact
with several transcription factors and transcription
regulators ([Jung et al., 2005a] and Chooniedass-Kothari
et al., personal observations). As a result of a concerted
effort to generate a database of proteins interacting with
nuclear receptor coregulators [Jung et al., 2005b; Jung
et al., 2005a], a series of SRAP-interacting proteins has
been recently listed.These proteins have been identified
by coimmunoprecipitation of nuclear or cytoplasmic
extracts from nuclear HeLa cell extracts using
commercially available polyclonal rabbit anti-SRAP
antibodies (Bethyl Laboratories, Inc.). As shown in Table
3, among the 54 proteins characterized as
coimmunoprecipitating with SRAP, are protein
chaperones and proteins involved in transport.
Interactions with such molecules either reflect a
"house-keeping" stage (folding, stabilization and transport)
of the SRAP protein processing (common to many
proteins), or indicate its possible functional involvement
in these processes.The identification, however, of a large
number of partners directly involved in RNA processing,
regulation of transcription or DNA replication strongly
suggests that SRAP may play a role in gene expression.
The characterization of p68 (DDX5) as a SRAP-interacting
protein is of particular interest, as it underlines the
likelihood of crosstalk between SRA RNA and SRAP
signaling. Altogether, emerging data suggest that SRAP,
similar to its RNA counterpart, might also participate in
the regulation of transcription.The exact roles of SRAP
on nuclear receptor signaling pathways remain to be
elucidated.
Coding/noncoding SRA RNAS: possible
regulatory mechanisms?
Understanding how cells could regulate such a bifaceted
system, involving both noncoding and coding RNAs,
possibly sending contradictory and/or intertwined signals
to the transcriptional machinery, represents an important
question that currently remains unexplored. It has
however been demonstrated that both coding and
noncoding SRA RNAs coexist in breast cancer cells and
that their relative proportions vary from one cell line to
another [Hube et al., 2006].The retention of intron-1,
which introduces a shift in the SRAP reading frame and
results in the production of noncoding SRA RNAs, has
therefore been proposed as a potential mechanism used
by cells to control the balance between these two RNA
species.
The demonstrated nuclear function of noncoding SRA
RNAs (i.e., coactivation of nuclear receptor), together
with the existence of SRAP (resulting from the translation
of coding RNAs), underlines the need for these transcripts
to be present, at least temporarily, in a specific cell
compartment. Such a need suggests that cells, through
controlling the cellular localization of SRA transcripts,
might have a simple way to regulate the functional effects
of both partners. One might speculate that cis-elements,
located within the transcripts or at their 5' or 3' extremities
could, as described in other systems [Chabanon et al.,
2004; Jambhekar and Derisi, 2007; Kindler et al., 2005;
Li et al., 2006], participate in the targeting of a given RNA
to a particular cellular compartment. In situ hybridization
results have corroborated the likelihood of the existence
of cellular mechanisms regulating the localization of SRA
transcripts. Indeed, whereas SRA RNA is detected mainly
in the nucleus of transgenic mice mammary epithelial
cells overexpressing SRA [Lanz et al., 2003], this
transcript is primarily found in the cytoplasm of transiently
transfected MCF-7 breast cancer cells [Zhao et al., 2007].
Interestingly, these two groups used the same SRA
construction (SRA II, see Figure 1A). Besides possible
differences in the 5' and 3' extremities introduced by
construction variations (such as different transcription
start sites), which might contribute to the observed
differential localization of SRA RNAs in the two systems,
one might speculate that normal [Lanz et al., 2003] and
cancer [Zhao et al., 2007] cells could differentially target
the same SRA sequence. Studies are critically needed
to fully characterize the mechanisms controlling the
generation and the localization of noncoding and coding
SRA RNAs, as well as their possible impact on breast
tumorigenesis and breast tumor progression.
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The overexpression of SRA core sequence during breast
tumorigenesis, together with a higher expression of SRAP
in patients more likely to survive under Tamoxifen
treatment, make the study of these molecules highly
relevant to breast cancer research. Indeed, one might
foresee that the full understanding of this bifaceted system
might provide new targets for curative or preventive
strategies to fight this disease. Unfortunately, the
complexity of the bifaceted SRA/SRAP system makes
function difficult to address. For example, the
interpretation of specific experiments performed using
approaches decreasing SRA RNA [Caretti et al., 2006;
Cavarretta et al., 2002; Hatchell et al., 2006; Kurisu et
al., 2006] might be impaired by the fact that both RNA
and protein are likely affected.This makes such
approaches unsuitable for the further dissection of
respective mechanisms of action of these two
protagonists. It is likely that new techniques, specifically
targeting the RNA or the protein production/function, will
be needed to overcome this problem.
SRA can now definitively be seen as a functional coding
RNA. It provides a fascinating link between two worlds,
which, up to now, appeared to be quite delineated.
Indeed, functional RNAs were thought to be inherently
different from their messenger counterparts [Costa, 2005;
Mattick, 2001]. mRNAs (coding RNAs) were only seen
as a transitional step of genetic information, a passive
link between DNA and a defined biological function filled
by the corresponding protein.The duo SRA/SRAP is now
forcing us to reconsider this concept.
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